<DOC>
	<DOCNO>NCT01769937</DOCNO>
	<brief_summary>Systemic lupus erythematosus serious potentially life-threatening condition significant unmet medical need . The aim Investigator Initiated , single center , open-label study evaluate efficacy safety daily subcutaneously ( SQ ) injection H.P . Acthar Gel 10 day optional 5 day rescue period non-responders day 10 dose . The primary objective study evaluate whether addition H.P . Acthar Gel standard treatment lupus ameliorate intensity flare measure change SLEDAI score , Patient Physician global assessment .</brief_summary>
	<brief_title>Open-label Trial Acthar Gel Subjects With Moderate Severe Active Systemic Lupus Erythematosus</brief_title>
	<detailed_description>This Phase 4 Open-label Study Evaluate Treatment Lupus Flares H.P . Acthar Gel . The primary objective evaluate whether addition H.P . Acthar Gel standard treatment lupus ameliorate intensity flare measure change SLEDAI score , Patient Physician global assessment . The secondary objective evaluate change subject BILAG score marker inflammation , e.g . ESR and/or CRP . The Exploratory objective determine feasibility long-term double-blind study use H.P . Acthar Gel versus usual treatment lupus .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Subjects must meet following criterion : 1 . In opinion investigator , must adequate reading write ability ( native language ) subject comprehend complete informed consent , protocolrelated assessment 2 . Age 1875 year time screen 3 . Written inform consent locally require authorization ( eg . HIPAA ) obtain subject prior performing protocolrelated procedure , include screen evaluation 4 . Fulfills least 4 11 American College Rheumatology ( ACR ) classification criterion SLE , include history ANA positivity 5 . Diagnosis pediatric adult SLE chronic disease activity require ongoing treatment observation &gt; 8 week prior screen . 6 . Currently receive least one following : 1 . A stable dose oral prednisone ( equivalent ) &lt; 20mg/day least 4weeks ( 28 day ) prior sign inform consent 2 . Any following medication administer stable dose minimum 8 week ( 56 day ) prior sign inform consent form ) Azathioprine ii ) Antimalarials ( eg . Chloroquine , hydroxychloroquine , quinacrine ) iii ) Mycophenolate mofetil/mycophenolic acid iv ) Weekly administration oral SQ Methotrexate 7 . At screen randomization ( Day 0 ) must meet SLE Flare criteria 8 . Females childbearing potential must use effective method birth control avoid pregnancy screen 90 day final dose Acthar unless surgically sterile ( i.e . bilateral tubal ligation , bilateral oophorectomy , complete hysterectomy ) , sterile male partner , 1 year postmenopausal , practice abstinence . Any follow would exclude subject participation study : 1 . Any condition , opinion investigator , would interfere evaluation investigational product confound interpretation subject safety study result 2 . Concurrent enrollment clinical study investigational product 4 week ( 28 day ) prior Day 0 within 5 halflives investigational product use clinical study , whichever longer 3 . Employees clinical study site individual involve conduct study immediate family member individual 4 . Any new oral prednisone therapy ( equivalent ) change current oral prednisone dose ( equivalent ) anytime 4 week ( 28 day ) prior sign inform consent 5 . A known history allergy reaction component investigational product 6 . Any live attenuate vaccine within 4 week ( 28 day ) prior sign inform consent form ( administration kill vaccine acceptable ) 7 . Diagnosis scleroderma , osteoporosis , fungal infection , ocular herpes simplex , surgery within past 4 week ( 28 day ) plan surgery within next 4 week ( 28 day ) 8 . History presence peptic ulcer , congestive heart failure , uncontrolled hypertension , primary adrenocortical insufficiency adrenocortical hyperfunction sensitivity proteins porcine origin 9 . Known history primary immunodeficiency underlie condition human immunodeficiency virus ( HIV ) infection splenectomy predisposes subject infection 10 . History type malignancy &lt; 5 year randomization study ( apart basal cell carcinoma ) 11 . Receipt one prescribed NSAID antiinflammatory dose 4 week ( 28 day ) prior Day 0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
	<keyword>ACTH</keyword>
	<keyword>Acthar</keyword>
</DOC>